🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Did you know prostate cancer is the most common cancer seen in men? This Men's Health Awareness Month, Dr. Pico, hematologist & oncologist Memorial Cancer Institute, discusses the importance of annual check ups & prostate cancer screenings starting at the age of 50. 👉mhs.net/cancer

Cabo+atezo in CRPC = ⬆️ rPFS (6.3 vs 4.2 mo HR 0.65(0.50-0.84). Immature OS 0.79(0.58-1.07). RR 13 vs 4%.We know Cabo mono has activity, and PD(L)1 has failed in CRPC. Therefore, without a Cabo mono arm it’s hard to know how much atezo is adding. Great job Neeraj Agarwal, MD, FASCO 👌⭐️#GU24

#BRCAAway is still the most convincing reason to me that we should combine PARP with novel hormonal treatments — combo olaparib-abiraterone better than each monotherapy. Congrats #MahaHussain & team for this careful trial guiding #prostatecancer care. #GU24 ASCO OncoAlert

Excited for another GU ASCO in San Francisco celebrating 20 years of this excellent symposium! Great opening session in PC with talks by Dr M Hussain, Neeraj Agarwal, MD, FASCO, Dr K Hoffman and Dr C Hennequin #gu24 ASCO

Interim analysis of ANTICIPATE phase II trial presented by Matt Galsky showed pCR of 39% in APL-1202/Tislelizimab combination vs 21% Tislelizumab alone given as NACT in MIBC for cisplatin ineligible/declining pts with an acceptable safety profile. #GU24 ASCO

With a median FU up of ~5 yrs adjuvant pembro= 38% reduction in risk of death. The benefit is across subgroups (T stage etc). Subsequent therapy in 80% is relapses. The 1st +ve OS adjuvant PD1 study, making adjuvant pembro more attractive. #GU24 Toni Choueiri, MD

51 years in the making till #GU24. OS benefit in adjuvant Renal Cancer is finally here. #KYN564

.Forbes names the University of Florida a “New Ivy” — recognizing UF’s top-performing graduates and the university leading higher education's evolution. news.ufl.edu/2024/04/forbes…

Disappointing Results for Gilead’s Phase 3 TROPiCS-04 Study! ⭕️ Sacituzumab govitecan (Trodelvy) in metastatic urothelial cancer did not meet the primary endpoint of overall survival. ⭕️Increased deaths due to neutropenic complications were noted in the Trodelvy group. #Asco24

DFF332 (HIF2a inhibitor) was tested in heavily pretreated RCC. 5% response rates and some stable disease. HIF biomaker looked unhelpful, but more to do here. Belzutifan seems more active as a single again #ASCO24 Sumanta K. Pal, MD, FASCO

Celebrating our ASCO FASCO designation with Narjust Florez, MD, FASCO Clarissa Mathias Charu Aggarwal, MD, MPH, FASCO Raymond O. Edgardo S. Santos, M.D., FACP, FASCO Rami Manochakian MD, FASCO Cancer Education Edgardo S. Santos, M.D., FACP, FASCO #lungcancer #lcsm several IASLC members awarded today

Preliminary SURE1 data shows neoadjuvant sacituzumab govitecan (n=21) required dose changes & GCSF to overcome toxicity. 33% didn’t have surgery making having responded efficacy hard to interpret. The trial goes on. pCR and ctDNA suggest activity but not transformative #ASCO24

FASCO awards at ASCO with Everett Vokes Narjust Florez, MD, FASCO Toni Choueiri, MD Edgardo S. Santos, M.D., FACP, FASCO Edgardo S. Santos, M.D., FACP, FASCO Rami Manochakian MD, FASCO Cancer Education Charu Aggarwal, MD, MPH, FASCO Pasi Janne and Raymond O. Mathew Gubbens and others! #lungcancer #lcsm #cancer

Proud to be an investigator of this first-in-human phase I clinical trial for multiplexed T-cell receptor engineered T-cell therapy (TCR-T) for solid tumors. Come check out our poster at #ASCO24 #ASCO Memorial Cancer Institute !

First two days of #ASCO24 have been stellar thus far. Over 40,000 in-person and virtual attendees who share a common goal. Nothing like it. Grateful to be here to collaborate and learn. Memorial Cancer Institute

Perhaps the most important long-term bladder cancer data #ASCO24 Neoadjuvant Toripalimab & disitimab Vedotin in muscle invasive bladder cancer (n=47). pCR ⬆️ 63%. 14% G3/4 AEs. All surgeries occurred . The 1st MMAE/IO neoadjuvant combo data looks ✅✅. EV/IO MIBC trials awaited

Thank you Javier Romero and Univision 23 Miami for the invitation to discuss prostate cancer and the importance of early detection on their program, 'Contigo en la Comunidad'. Episode airs Saturday on Univisión. Memorial Healthcare System

💫🌟📝 Key findings from the pembrolizumab study in kidney cancer: OncoAlert OncoReporte 🔬 First adjuvant therapy to improve overall survival in kidney cancer. 🧑‍🤝‍🧑 91% of patients on pembrolizumab alive at 4 years vs. 86% on placebo. ⏳ 40% reduction in the risk of death with

PORTOS predicts RT dose benefit in localized prostate cancer! Shuang Zhao, MD 🧬☢️In two phase III trials (NRG/RTOG 0126 & SAKK 09/10), the 24-gene PORTOS score identified patients who benefited from radiation dose escalation. @asco @oncoalert #GU25 #cancer #oncology

TALAPR02 looks at Talazoparib/enza vs enza in 1st line CRPC . It has significant OS in ITT HR=0.796. It’s current used in HRR deficient. Subset analysis and wider data still supports the HRR biomarker OS (HRR deficient HR -0.54, HRR non-defficent/NA 0.87), but ITT OS is +ve #GU25